[{"address1": "1 Ashley Road", "address2": "3rd Floor", "city": "Altrincham", "zip": "WA14 2DT", "country": "United Kingdom", "website": "https://www.centessa.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders. The company also develops LB101, a PD-L1xCD47 LockBody, a bi-specific monoclonal antibody for solid tumors, which is designed to selectively drive potent CD47 and CD3 effector function activity while avoiding systemic toxicity; and OX2R Agonists compounds are currently in development for the treatment of narcolepsy. In addition, its products pipeline comprises ORX750, an orally administered selective orexin receptor-2 (OX2R) agonist for the treatment of narcolepsy and other sleep disorders; and earlier-stage preclinical assets and discovery-stage programs. Centessa Pharmaceuticals plc was incorporated in 2020 and is headquartered in Altrincham, the United Kingdom.", "fullTimeEmployees": 72, "companyOfficers": [{"maxAge": 1, "name": "Dr. Saurabh  Saha M.D., Ph.D.", "age": 47, "title": "CEO & Director", "yearBorn": 1976, "fiscalYear": 2023, "totalPay": 1041809, "exercisedValue": 0, "unexercisedValue": 6715049}, {"maxAge": 1, "name": "Dr. David M. Chao Ph.D.", "age": 55, "title": "Chief Administrative Officer", "yearBorn": 1968, "fiscalYear": 2023, "totalPay": 710304, "exercisedValue": 0, "unexercisedValue": 98467}, {"maxAge": 1, "name": "Mr. John J. Crowley CPA", "age": 49, "title": "CFO and Principal Financial & Accounting Officer", "yearBorn": 1974, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Tia L. Bush", "age": 52, "title": "Chief Technology & Quality Officer", "yearBorn": 1971, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Kristen K. Sheppard Esq., J.D.", "title": "Senior Vice President of Investor Relations & Corporate Communications", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Iqbal J. Hussain L.L.B.", "age": 42, "title": "General Counsel, Chief Compliance Officer & Corporate Secretary", "yearBorn": 1981, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Karen M. Anderson", "age": 55, "title": "Chief People Officer", "yearBorn": 1968, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Gregory M. Weinhoff M.B.A., M.D.", "age": 52, "title": "Chief Business Officer", "yearBorn": 1971, "fiscalYear": 2023, "totalPay": 655004, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Mario Alberto Accardi Ph.D.", "title": "President of the Orexin Program", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. April  Dovholuk", "title": "Senior Vice President of Development Operations", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 2, "previousClose": 15.5, "open": 15.57, "dayLow": 15.165, "dayHigh": 15.61, "regularMarketPreviousClose": 15.5, "regularMarketOpen": 15.57, "regularMarketDayLow": 15.165, "regularMarketDayHigh": 15.61, "beta": 1.469, "forwardPE": -9.064327, "volume": 170175, "regularMarketVolume": 170175, "averageVolume": 589585, "averageVolume10days": 269630, "averageDailyVolume10Day": 269630, "marketCap": 1992819456, "fiftyTwoWeekLow": 5.583, "fiftyTwoWeekHigh": 17.59, "priceToSalesTrailing12Months": 290.7952, "fiftyDayAverage": 15.0206, "twoHundredDayAverage": 11.0515, "currency": "USD", "enterpriseValue": 1547186560, "floatShares": 76206130, "sharesOutstanding": 128569000, "sharesShort": 2012240, "sharesShortPriorMonth": 1502616, "sharesShortPreviousMonthDate": 1726185600, "dateShortInterest": 1728950400, "sharesPercentSharesOut": 0.015700001, "heldPercentInsiders": 0.01413, "heldPercentInstitutions": 0.77927, "shortRatio": 3.66, "shortPercentOfFloat": 0.019299999, "impliedSharesOutstanding": 128569000, "bookValue": 2.536, "priceToBook": 6.111987, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1719705600, "netIncomeToCommon": -157347008, "trailingEps": -1.55, "forwardEps": -1.71, "enterpriseToRevenue": 225.768, "enterpriseToEbitda": -9.975, "52WeekChange": 1.3484848, "SandP52WeekChange": 0.39389753, "exchange": "NMS", "quoteType": "EQUITY", "symbol": "CNTA", "underlyingSymbol": "CNTA", "shortName": "Centessa Pharmaceuticals plc", "longName": "Centessa Pharmaceuticals plc", "firstTradeDateEpochUtc": 1622208600, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "9f3bdf1d-ddc8-3bbd-88f7-8fed1cc82ba8", "messageBoardId": "finmb_704505677", "gmtOffSetMilliseconds": -14400000, "currentPrice": 15.5, "targetHighPrice": 35.0, "targetLowPrice": 19.0, "targetMeanPrice": 26.14, "targetMedianPrice": 24.0, "recommendationMean": 1.5, "recommendationKey": "strong_buy", "numberOfAnalystOpinions": 7, "totalCash": 294832992, "totalCashPerShare": 2.602, "ebitda": -155099008, "totalDebt": 85648000, "quickRatio": 12.776, "currentRatio": 13.287, "totalRevenue": 6853000, "debtToEquity": 29.846, "revenuePerShare": 0.068, "returnOnAssets": -0.24543, "returnOnEquity": -0.55839, "freeCashflow": -91917752, "operatingCashflow": -146308000, "grossMargins": 1.0, "operatingMargins": -22.684519, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-10-28"}]